


# Amendments to the Claims:

Claims 1-12. (Cancelled)

13. (Currently Amended) A pharmaceutical composition ~~in accordance with claim 1 for the~~ treatment of cancer comprising

an effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms, wherein said compound has the formula:



where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 to 3; b is 0 to 3; R''' is H, SO<sub>3</sub><sup>-</sup>, PO<sub>4</sub><sup>2-</sup>, CO<sub>2</sub>H, OH, (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, S(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, or NR''''C(O)(R''''') where R'''' and R''''' are (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>; and n is 0 to 6; and  
a pharmaceutically acceptable excipient.

Claims 14-19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition in accordance with claim 13, wherein L and L' are independently selected from the group consisting of PR<sub>3</sub>, P(OR)<sub>3</sub>, CNR, NCR, PR<sub>n</sub>(CH<sub>2</sub>OR<sup>†</sup>)<sub>3-n</sub>, N<sub>4</sub>C<sub>6</sub>H<sub>12</sub>, [N<sub>4</sub>C<sub>6</sub>H<sub>12</sub>-N-CH<sub>3</sub>]<sup>+</sup>, PN<sub>3</sub>C<sub>6</sub>H<sub>12</sub>, and P[N<sub>3</sub>C<sub>6</sub>H<sub>12</sub>-N-CH<sub>3</sub>]<sup>+</sup>, where R is a substituted or unsubstituted hydrocarbon moiety and R<sup>†</sup> is selected from the group consisting of H, Me, SO<sub>2</sub><sup>-</sup>, PO<sub>3</sub><sup>-</sup>, alkyl and aryl, and each R<sup>†</sup> in any one ligand is the same or different.


21. (Original) A pharmaceutical composition in accordance with claim 20, wherein R is a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group and each R in any one ligand is the same or different.

22. (Previously Presented) A pharmaceutical composition in accordance with claim 20, wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl and phenyl groups.

23. (Previously Presented) A pharmaceutical composition in accordance with claim 20, wherein the ligand is  $\text{PPh}_3$ .

Claims 24-40. (Cancelled).


41. (New) A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound selected from the group consisting of:



; and

a pharmaceutically acceptable excipient.

42. (New) A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms, wherein said compound has the formula:



where: L and L' are ligands; R' and R'' are each independently selected from the group consisting of methylene, ethylene, propylene, butylene and phenylene groups; a is 0 to 3; b is 0 to 3; R''' is H, SO<sub>3</sub><sup>-</sup>, PO<sub>4</sub><sup>2-</sup>, CO<sub>2</sub>H, OH, (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, S(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, or NR''''C(O)(R''''') where R'''' and R''''' are (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>; and n is 0 to 6; and a pharmaceutically acceptable excipient.

43. (New) A pharmaceutical composition in accordance with claim 42, wherein L and L' are independently selected from the group consisting of PR<sub>3</sub>, P(OR)<sub>3</sub>, CNR, NCR, PR<sub>n</sub>(CH<sub>2</sub>OR<sup>†</sup>)<sub>3-n</sub>, N<sub>4</sub>C<sub>6</sub>H<sub>12</sub>, [N<sub>4</sub>C<sub>6</sub>H<sub>12</sub>-N-CH<sub>3</sub>]<sup>+</sup>, PN<sub>3</sub>C<sub>6</sub>H<sub>12</sub>, and P[N<sub>3</sub>C<sub>6</sub>H<sub>12</sub>-N-CH<sub>3</sub>]<sup>+</sup>, where R is a substituted or unsubstituted hydrocarbon moiety and R<sup>†</sup> is selected from the group consisting of H, Me, SO<sub>2</sub><sup>-</sup>, PO<sub>3</sub><sup>-</sup>, alkyl and aryl, and each R<sup>†</sup> in any one ligand is the same or different.

44. (New) A pharmaceutical composition in accordance with claim 43, wherein R is a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group and each R in any one ligand is the same or different.

45. (New) A pharmaceutical composition in accordance with claim 43, wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl and phenyl groups.

46. (New) A pharmaceutical composition in accordance with claim 43, wherein the ligand is  $\text{PPh}_3$ .